Key result
Platelet FcγRIIa demonstrates clinical utility as a cardiovascular risk marker in patients with acute myocardial infarction.
Why the study?
Does platelet FcγRIIa serve as a cardiovascular risk marker in patients with acute myocardial infarction?
Does platelet FcγRIIa serve as a cardiovascular risk marker in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
The study investigates the clinical utility of platelet FcγRIIa as a cardiovascular risk marker in patients with acute myocardial infarction.
Myocardial infarction (MI) and related cardiovascular events (CVEs) are leading global health burdens. Current acute coronary syndrome (ACS) guidelines recommend dual antiplatelet therapy for at...
No takes yet. Share an insight, caveat, or question.
Hallak et al. (2025) studied this question. Platelet FcγRIIa demonstrates clinical utility as a cardiovascular risk marker in patients with acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: